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Summary 
CD28 costimulatory signals are required for lympho- 
kine production and T cell proliferation. CD28 signal- 
ing recruits the intracellular proteins PI 3-kinase, ITK, 
and GRE2ISOS. PI 3-kinase and GRB-S/SOS bind the 
CD28 cytoplasmic pYMNM motif via SH2 domains. We 
generated CD28 pYMN# mutants and found that Ylsl 
mutation (Y1%D28F) disrupted both PI 3-kinase and 
GRB-2 binding, while M’” mutation (Mls4CD28C) dis- 
rupted only PI 3-kinase binding. Both mutants still 
bound ITK. We have assessed the ability of these se- 
lective mutants to support IL-2 production upon TCRLj 
CD3 ligation in the presence of CHO-CD88 (B7-2) cells. 
Both Y1%D28F and M’“CD28C mutants failed to gen- 
erate IL-2. These data directly implicate PI 3-kinase in 
CDSI-media&d costimulation leading to IL-2 secretion. 
Wortmannin, an inhibitor of PI 3-kinase, induced cell 
apoptosis and as such was unsuitable for use in this 
study. 
Introduction 
Ligation of the antigen receptor on the surface of T cells 
(T cell receptor [TCR]qCD3) alone is insufficient to induce 
resting T lymphocytes to produce maximal levels of in- 
terleukin 2 (IL-2) and optimal proliferation (Schwartz, 
1992). Additional ligand-receptor interactions on antigen- 
presenting cells (APCs) and T cells are required. The best 
characterized among these costimulatory pairs is CD28 
and its binding partnersCD80 (87-l) and CDSS(B7-2; 870) 
(Jenkinsand Johnson, 1993; Linsleyand Ledbetter, 1993). 
While both ligands are expressed constitutively on macro- 
phages and hendritic cells, CD86 is expressed more rap- 
idly and at higher levels (Azuma et al., 1993; Freeman et 
al., 1993a; Hathcocket al., 1993,1994). Both ligands bind 
CD28 with similar avidity, but CD86 exhibits a higher rate 
of dissociation (Linsley et al., 1994). CD28-deficient mice 
show reduced T cell responses to allogeneic APCs, anti- 
CD3 plus anti-CD28 or APC-B7-1, and exhibit reduced T 
cell-dependent humoral responses (Green et al., 1994; 
Shahinian et al., 1993). Similarly, CD80-negative mice ex- 
hibit reduced immune responses (Freeman et al., 1993b). 
In certain settings, the activation of T cell helper (Th)l 
cells without costimulation results in unresponsiveness to 
further challenge by antigen (Jenkins et al., 1988; Koulova 
et al., 1991; Schwartz, 1992). Much of CD28 costimulation 
is elicited indirectly via an effect on lymphokine produc- 
tion. Nonresponsiveness can be bypassed by IL-2, 11-4, 
or IL-7via signaling through a common y chain (Boussiotis 
et al., 1993, 1994). 
The importance of CD28 in T cell responses is further 
underlined by the findings that the generation of cytolytic 
responses against tumors can be regulated by ligation 
of this receptor (Baskar et al., 1993; Chen et al., 1992; 
Townsend and Allison, 1993). Furthermore, overexpres- 
sion of CD80 together with an immunogenic antigen in 
pancreatic islets results in rapid autoimmune insulitis 
(Guerder et al., 1994), and the blockage of interaction be- 
tween CD28 and 87 induces antigen tolerance and pro- 
longs survival of transplants (Lenschow et al., 1992; Lins- 
ley et al., 1992a). CD28 also stabilizes mRNA for various 
lymphokines such as interleukin 2 (IL-2), and induces the 
expression of CTLA4 and the CD40 ligand (Fraser et al., 
1991; Lindsten et al., 1989). Recent studies suggest that 
CD80 and CD86 differentially regulate cytokine production 
(Kuchroo et al., 1995; Lenschow et al., 1995; Freeman et 
al., 1995). 
CD28 could control any or all of these events by means 
of its interaction with phosphatidylinositol 3-kinase (PI 
3-kinase), GRB9/SOS, or ITK (Truitt et al., 1994; Prasad 
et al., 1994; August and DuPont, 1994; Schneider et al., 
1995a; August et al., 1994). The cytoplasmic tail of the 
receptor carries the phosphotyrosine-based motif 
pYMNM, which can bind with high affinity to the SH2 do- 
mains of PI 3-kinase and GRB-2 (Prasad et al., 1994; 
Schneider et al., 1995a). PI 3-kinase is comprised of a 
heterodimer consisting of an adaptor subunit (~85) with 
two SH2 domains that is coupled to a ~110 catalytic 
subunit (Carpenter et al., 1990; Dhand et al., 1994a; Par- 
ker and Waterfield, 1992). It is a bifunctional kinase, a 
serine kinase (Dhand et al., 1994b), and a lipid kinase 
that phosphorylates the D-3 position of the inositol ring 
of phosphatidylinositol, phosphatidylinositol4-phosphate, 
and phosphatidylinositol4,5 bisphosphate, generating PI 
3-P, PI 3,4-P2 and PI 3,4,5-P3. Engagement of CD26 in- 
duces the recruitment of PI 3-kinasewith the receptor (Pra- 
sad et al., 1994; Truitt et al., 1994). Site-directed mutagen- 
esis and peptide binding analysis showed that the CD28 
pYMNM motif binds to the ~85 C- and N-terminal SH2 
domains with an avidity comparable to that observed for 
PDGF-R and IRS-l. The C-terminal SH2 domain binds to 
the CD28 pYMNM motif with some lo-fold greater affinity 
than the N-terminal domain (Prasad et al., 1994). Given 
the importance of the PI 3-kinase binding to a similar motif 
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in the PDGF-R (Fantl et al., 1992; Valius and Kazlauskas, 
1993) PI 3-kinase is a potential candidate in providing 
second signals required for T cell proliferation (Rudd et 
al., 1994). CTLA4 has also been found to bind to PI 
3-kinase by means of a pYVKM motif (Schneider et al., 
1995b). 
SOS (Son of Sevenless) is a guanine nucleotide ex- 
change factor that activates p21r”, by converting it from 
a GDP- to GTP-bound state (Bonfini et al., 1992; Simon 
et al., 1993). GRB-2 is an SH3-SH2-SH3 adapter subunit, 
which uses its SH3 domain to bind to proline residues 
within SOS, while using its single SH2 domain to bind the 
phosphotyrosine-based motifs of surface receptors (Si- 
mon et al., 1993). GRB-2 is recruited by CD28 by binding 
to the pYMNM motif in response to antibody ligation 
(Schneider et al., 1995a). CD28 may recruit GRB-P/SOS 
from the cytosol to the cell membrane where it should be 
well placed to regulate ~21’“. Indeed, anti-CD28-mediated 
cross-linking of CD28 has been reported to activate p21raS 
(Nunes et al., 1994) and downstream targets MAP kinase 
(MAPK; ERK 1,2) and Jun kinase (JNK) (August and Du- 
Pont, 1994; Nunes et al., 1994; Su et al., 1994). ~21’” is 
required for TCR-mediated IL-2 production (Rayter et al., 
1992; Baldari et al., 1993). Despite the sharing of a com- 
mon binding motif, PI 3-kinase does not prevent GRB-2 
binding and vice versa. Based on peptide binding, the 
GRB-2 SH2 domain binds to CD28 with a considerably 
lower avidity than the PI 3-kinase SH2 domains. However, 
this may underestimate the avidity of binding, since sec- 
ondary points of contact may exist. Consistent with this, 
mutation of Y-191 significantly reduced, but did not com- 
pletely eliminate GRB-2 binding (Schneider et al., 1995a). 
CD28 has also been reported to bind to the nonreceptor 
tyrosine kinase ITK (EMT/TSK) (August et al., 1994). Non- 
receptor tyrosine kinases can interact with cell surface 
receptors, as initially shown with CD4-~58’~” (Rudd et al., 
1994). ITK is structurally related to members of the src 
family with an unique N terminus, an SH3 and SH2 do- 
main, aswell asa kinasedomain. However, it sharesgreat- 
est homology with members of the Tee family of tyrosine 
kinase. It is restricted to T cells, being expressed at the 
highest level on the thymus (Desiderioet al., 1993; Heyeck 
and Berg, 1993). CD28 ligation is required to activate and 
recruit ITK from the cytoplasm (August et al., 1994). The 
molecular basis of CD28 binding to ITK has yet to be estab- 
lished. 
The involvement of the phosphotyrosine-based 
CD28pYMNM motif in recruiting downstream molecules 
implicates an intervening protein-tyrosine kinase in the 
regulation of costimulation. p581Ck and p59bn can fufill this 
function by phosphorylating CD28 at Y-191, which in turn 
facilitates the recruitment of ~85 and GRB-2 (Raab et al., 
1995). ZAP-70 and ITK failed to induce the formation of 
CD28-intracellular ligand complexes. Despite the involve- 
ment of src kinases, CD28 appears to act as an indepen- 
dent signaling unit. Anti-CD28 ligation of peripheral T cells 
can induce the recruitment of PI 3-kinase and GRB-2, with- 
out prior TCR ligation (Prasad et al., 1994; Schneider et 
al., 1995c; Truitt et al., 1994). Further, src kinases have 
been reported to coprecipitate with CD28 in gentle deter- 
gents (Hutchcroft and Bierer, 1994). 
By binding to multiple intracellular signal-transducing 
molecules, CD28 may engage multiple signaling cas- 
cades in T cells. Different CD28 signaling pathways may 
selectivelyregulateevents, such asan increase in lympho- 
kine production, and the expression of CTLA-4 and the 
CD40 ligand. Pages et al. (1994) demonstrated the impor- 
tance of the pYMNM motif by showing that the mutation 
at Y-191 prevented the ability of anti-CD28 antibodies to 
produce IL-2. However, this mutation disrupts both PI 
3-kinase and GRB-2 binding, and did not distinguish the 
roles played by PI-3 kinase, GRBQISOS, or ITK in TCR- 
CDPSmediated costimulation. Other attempts to address 
this question using wortmannin, an inhibitor of PI 3-kinase, 
to block CD28 induced IL-2 production have resulted in 
contradictory findings (Lu et al., 1995; Ward et al., 1995). 
To address the role of CD2Sassociated PI 3-kinase in 
costimulation, we assessed the ability of CD28-PI 
3-kinase binding mutants to induce IL-2 production in a 
costimulation system dependent on TCRTJCD3 and CD28 
coligation. While wild-type CD28 supported IL-2 produc- 
tion, a SH2 binding mutant (Ylg1CD28F) and a selective 
PI 3-kinase binding mutant (M’%CD28C) failed to support 
IL-2 production, or to recruit the kinase. While the 
Mlg4CD28C mutant failed to bind to PI 3-kinase, it retained 
an ability to bind to GRB-2 and ITK. These data implicate 
CD28-PI 3-kinase in CD28 regulation of IL-2 production. 
Results 
Human CD28 Mediates AntXD8Dependent 
IL-2 Production 
The T cell hybridoma DC27 was transfected with human 
CD28 and assessed for the ability to respond to anti-CD3 
in the presence of CHO cells expressing CD88 (97-2). The 
murine hybridoma has been previously described (Gabert 
et al., 1987). Transfected human CD28 was expressed at 
least 20 times greater than the endogenous murine CD28, 
as detected by immunofluorescence staining (Figure 1A). 
Biotinylation of cells followed by immunoprecipitation with 
anti-CD28 confirmed this observation (Figure 19). A broad 
band at 40-50 kDa corresponding to CD28 was precipi- 
tated by anti-mouse CD28 (Figure 1, lane 3) and anti- 
human CD28 (lane 4). Densitometric readings showed ap- 
proximately 40 times greater human CD28 (hCD28) than 
endogenous murine CD28 (Figure 1, lane 4 versus lane 3). 
High levels of hCD28 expression allowed us to establish 
a model system to examine the role of the CD28 pYMNM 
motif in IL-2 production. Incubation of cells with anti-CD3 
antibody and CHO-CD86 cells induced high levels of IL-2 
production in hCD28-transfected cells (wild type) (Figure 
2). The response depended on the expression of CD86, 
since the incubation of the T cells with anti-CD3 alone or 
anti-CD3 plus untransfected CHO cells failed to generate 
IL-2. Similarly, CHO-CD86 plus anti-CD3 caused little IL-2 
production in vector-transfected cells. The low level of en- 
dogenous murine CD28 expression was insufficient to 
support IL-2 production at the lower levels of anti-CD3 
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Figure 1, Analysis of Human CD28 Expression in Transfected DC27 
Cells (Wild Type) 
(A) Analysis by flow cytometry of expression of murine CD3. murine 
CD28 (mCD28), and human CD28 (hCD28) using MAbs 2C11,37.51, 
and L293, respectively. The control corresponds to cell staining with 
secondary antibodies alone (FITC-conjugated goat anti-mouse MAb). 
(B) The SDS-PAGE profile of immunoprecipitates of biotinylated 
mCD28 and hCD28. DC27 cells were biotinylated and subjected to 
immunoprecipitation using MAbs as indicated (see Experimental Pro- 
cedures). lmmunoprecipitations with protein G-Sepharose (PGS) and 
rabbit anti-hamster antibodies plus protein G-Sepharose (RaH) served 
as negative controls. Lane 1, PGS; lane 2, RaH; lane 3, anti-mCD28; 
lane 4. anti-hCD28. 
antibody. At higher concentrations of anti-CD3 mono- 
clonal antibody (MAb), a slight contribution of endogenous 
murine CD28 was observed in parental untransfected 
DC27 cells; however, analysis using higher anti-CD3 con- 
centrations was complicated by a significant decrease in 
cell viability (Ucker et al., 1989; data not shown). Various 
anti-CD3 concentrations were tested in this system, with 
maximal levels of IL-2 observed at lo-” M. As a control for 
dependence on CD86 expression, anti-CD86 was found to 
inhibit CD86-mediated costimulation in a dose-dependent 
manner (Figure 3). Antibody concentration at about 0.5 
Kg/ml caused a 50% inhibition of the response. 
Involvement of pYMNM Residues Y-191 and M-194 
in CD28 Signaling 
To assess the role of PI 3-kinase in costimulation, we 
transfected DC27 cells with various mutated forms of hu- 
man CD28 that are defective in binding to PI 3-kinase. To 
allow study of the relative contributions of PI 3-kinase, 
GRB-2, and ITK binding, it was necessary to generate a 
form of CD28-carrying mutation that selectively disrupted 
PI 3-kinase binding. Y’%D28F within pYMNM abrogates 
binding to all SH2 domains, while the M’%D28C mutation 
should selectively disrupt PI 3-kinase binding (Prasad et 
al., 1994). To control for differences between individual 
cells, two transfectants were selected for the analysis of 
each mutation. The surface expression of the wild-type, 
Yqg1CD28F (YrsrF) and Mlg4CD28C (Mlg4C) were similar for 
most of the transfectants (Figure 4). One M’%D28C 
(Ml%) transfectant (termed Ml%-b) expressed CD28 at 
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Figure 2. IL-2 Production Is Dependent on Anti-CD3 in Conjunction 
with CD86 
IL-2 production in DC27 cells that were transfected with hCD28 (wild 
type) or vector was analyzed by incubation with anti-CD3, anti-CD3 
plus CHO, and anti-CD3 plus CHO-CD86. The vector or human CD28- 
transfected DC27 cells were cultured for 24 hr in the presence of 
anti-CD3 MAb (2C11, IO-” M) in medium alone (-). or together with 
Cl-IO or CHO-CD86 cells. Supernatants were harvested and analyzed 
for IL-2 in triplicates. Shown are typical results from one of six experi- 
ments. 
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Figure 3. IL-2 Production Induced by Anti-CD3 plus CHO-CD86 Is 
Blocked by Anti-CD86 MAb 
The costimulation assay was performed as in Figure 2 in the presence 
of anti-CD86 antibody (2DlO) at various concentrations. Antibodies 
were added at the start of culture. Results are expressed as a percent- 
age of IL-2 production in the absence of 2DlO MAb. 
somewhat higher levels, although this did not alter itsfunc- 
tional phenotype (see below). An examination of other sur- 
face markers such as murine CD28 and CD3 showed that 
expression levels were similar to those of the wild-type 
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Figure 4. Mutations at Y-191 and M-194 Abrogate Anti-CD3 plus 
CHO-CDIB-Induced IL-2 Production 
(A)Cellsurfaceexpression ofwild-typeandmutatedformsof hCD28on 
transfected DC27 cells was analyzed by flow cytometry. Background 
fluorescence of secondary MAb alone was subtracted. Wl represents 
the wild-type hCD28 transfectant, while F191 and Cl94 represent the 
mutations at Tyr-191 to Phe and Met-194 to Cys, respectively. Two 
cell populations were tested for each transfectant (indicated as a, b). 
(6, C) Y’O’ and M’” residues in pYMNM motif are required for CD28- 
induced IL-2 production. DC27 transfectants were incubated with 
CHO-CD86 and 2Cll (10~” M) for 24 hr, after which supernatants 
were assayed for IL-2 production (B). Each column includes standard 
deviation of triplicates. (C)depicts a separate experiment showing the 
inability of the F191 and Cl94 mutants to produce IL-2 in response 
to CHO-CD86 and different concentrations of anti-CD3 (lo-” to 
lo-l3 M). 
transfectant (unpublished data). Hence, mutations at 
these residues did not prevent expression of CD28 on the 
cell surface. 
We next examined the ability of Y1VD28F (F191) and 
M’%ZD28C (C194) mutants to support IL-2 production. 
While anti-CD3 plus CHO-CD86 induced high levels of 
IL-2 production (>200 U/ml) in the wild-type transfectant, 
the Y1g’CD28F and Mig4CD28C mutants secreted lympho- 
kine at markedly reduced levels (Figure 48). Each of the 
duplicate transfectants gave similar results. In both cases, 
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Figure 5. Y19’ and M lI” Residues in pYMNM Motif Are Required for 
Binding by PI 3-Kinase 
Different DC27 transfectants (vector, WT, F191. and C194) were incu- 
bated with CHO or CHO-CD88 cells as indicated at 37% for 0 (lane 
1) or 30 min (lanes 2-5), solubilized in NP-40 lysis buffer and immuno- 
precipitated with an anti-human CD28 antibody (L293). Precipitates 
were then labeled in an lipid kinase assay (A), or blotted using an 
anti-p85 antisera(C). Lanes 1 and 3, CHO-CD86 plus wild-type human 
CD28 transfectant; lane 2, CHO-CD86 plus vector-transfected DC27 
cells; lanes 4 and 5, CHO-CD86 plus F191- and C19Ctransfected 
cells, respectively. Lane 6 corresponds to an anti-p85 precipitation, 
while lane 7 represents a rabbit anti-mouse precipitation. (8) shows 
the PI 3-kinase activities in (A) expressed as a percentage of wild 
type; the intensity of each PI-P spot was determined by Ultra&an 
densitometry. 
IL-2 production was less than 10% of the wild-type control. 
Further, the two M199CD28C mutants showed a similar re- 
duction in IL-2 production, despite differences in the ex- 
pression of the receptor (Figure 4A). Similar results were 
observed when lo- to lOO-fold lower concentrations of 
anti-CD3 antibody were used (Figure 4C). Interestingly, 
the effect was noted at anti-CD3 concentrations as low 
as lo-l3 M, a concentration that is expected to approxi- 
mate the concentration of peptide present in physiological 
APC-T cell responses (Sykulev et al., 1994). 
Y-191 and M-194 Residues Are Required for PI 
3-Kinase Binding 
We next determined whether CHO-CD86 ligation of the 
transfected wild-type CD28 could recruit PI 3-kinase, and 
whether mutations at Y-191 and M-193 disrupted PI 
3-kinase binding. As seen in Figure 5A, anti-CD28 precipi- 
tated a small amount of associated PI 3-kinase activity 
from unligated cells (lane 1). By contrast, exposure of wild 
type to CHO-CD86 resulted in marked increase in CD28- 
associated PI 3-kinase as detected by kinase activity (Fig- 
CD2s-Mediated Signaling 
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ure 5A, lane 3 versus lanes 1 and 2) and the presence of 
p85 as detected by immunoblotting (Figure 5C, lane 3 
versus lanes 1 and 2). The increase in associated PI 
3-kinase activity was therefore primarily due to PI 3-kinase 
recruitment by CD28. Importantly, mutation at Y-191 
(Yqg’CD28F) reduced CD28-coprecipitated PI 3-kinase to 
background levels, as demonstrated by kinase analysis 
(Figure 5A, lane 4), and by anti-p85 immunoblotting (Fig- 
ure 5C, lane 4). A small amount of kinase activity was 
observed with the Cl94 mutant (Figure 5A, lane 5); how- 
ever, the amount of kinase was too low to be detected 
by anti-p85 immunoblotting (Figure 5C, lane 5). Anti-p85 
precipitates served as a positive contol (Figures 5A and 
5C, lane 6). 
To confirm the validity of the above observations, the 
interactions of wild-type CD28 and mutants with PI 
3-kinase were reconstituted in a baculoviral expression 
system. The expression of large amount of proteins in 
insect cells allows the detection of low levels of association 
between proteins. We have previously shown that the ex- 
pression of tyrosine kinases ~56”~ and p59b” with CD28 
regulates PI 3-kinase, GRB-2, and ITK binding to CD28 
(Raab et al., 1995). While coexpressed CD28 and PI 
3-kinase failed to bind to each other, the presence of ~56’“” 
and its ability to phosphorylate Y-l 91 allowed for the for- 
mation of CD28-PI 3-kinase complexes (Raab et al., 
1995). As shown in Figure 6A, under these conditions, 
wild-type CD28 was associated with PI 3-kinase (lane 1). 
By contrast, neither the Y1%D28F nor the M?ZD28C 
mutants were able to bind to PI 3-kinase (Figure 6A, lanes 
2 and 3). These data confirm that the mutation at Y-191 
and M-l 94 disrupted PI 3-kinase binding. 
To establish the specificity of the M-194 mutation in dis- 
rupting PI 3-kinase but not GRB-2 binding, the mutant 
was coexpressed with GRB-2 and Ick and assessed for 
binding. As shown in Figure 6B, the Y1%D28F mutant 
reduced binding to GRB-2 (lane 2), while M194CD28C had 
no effect when compared with wild type (lanes 1 and 3). In 
the case of ITK (Figure 6C), although we have had difficulty 
detecting the CD28-ITK interaction in T cells (data not 
shown), in coexpression studies mutations at neither 
Y-191 nor M-l 94 disrupted binding (lanes 3 and 4) when 
contrasted with wild-type CD28 (lane 2). The M-194 muta- 
tion therefore disrupts PI 3-kinase binding to CD28 without 
altering the binding of GRB-2 or ITK. 
Wortmannin, an Inhibitor of PI 3-kinase, Induces 
Apoptosis In T Cells 
Wortmannin has been reported to selectively inhibit PI 
3-kinase when used at low concentrations (Arcaro and 
Wymann, 1993; Yano et al., 1993). However, previous 
studies using this drug to inhibit CD28 costimulation in T 
cells have yielded contradictory results (Lu et al., 1995; 
Ward et al., 1995). This underlines the importance of our 
mutational analysis outlined in this study. Nevertheless, 
we also attempted to use this inhibitor to assess whether 
it could block eD28-induced IL-2 production. The addition 
of a range of wortmannin concentrations from 20-200 nM 
inactivated anti-CD28-precipitated PI 3-kinase (Figure 7A; 
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Figure 6. Mutational Analysis of CD28 Binding lo PI 3-Kinase, GRSP. 
and ITK 
Sf21 cells were infected with different combinations of recombinant 
baculoviruses (CD28, ~85, ~56”~, GRB-2, or ITK) as indicated. ITK 
was expressed as an HA-tagged protein. CD28 proteins were immuno- 
precipitated from cell lysates with antiCD28, and were subjected to 
Western blot analysis. The membranes were blotted with either anti- 
~85 (A), anti-GRBP (B), or anti-HA (C) antibodies. 
(A) F191 and Cl94 mutants failed lo bind ~85. Lane 1, coexpression 
of CD28, p561ck, and ~85; lane 2, F191 plus Lck and ~85; lane 3, Cl94 
plus Lck and ~85. 
(8) Cl94 mutant binds to GAB-P. Lane 1, coexpression of CD28, pE16~, 
and GRB-2; lane 2, F191 plus Lck and GRB-2; lane 3, Cl94 plus lck 
and GRB-2. 
(C) V1 and Cl94 mutants bind to ITK. Lane 1, coexpression of CD28 
plus HA-tagged ITK; lane 2. CD28 plus Lck and ITK; lane 3, F191 plus 
Lck and ITK; lane 4, Cl94 plus Lck and ITK. 
Figure 78, top), as well as anti-p85-precipitated kinase 
(Figure 7A; Figure 78, bottom). Densitometric readings 
indicated that the reagent inhibited the kinase activity by 
some 90% (Figure 7A). Under these conditions, wortman- 
nin caused a dramatic reduction of cell growth, as detected 
by [3H]thymidine incorporation and in cell viability, as as- 
sessed by trypan blue exclusion (Figure 7A). This effect 
was caused by concentration-dependent induction of apop 
tosis as revealed by DNA fragmentation (Figure 7C). Con- 
centrations as low as 10 nM induced significant DNA 
fragmentation in the DC27 cells. Although of interest, the 
apoptotic effect of wortmannin made this drug inappro- 
priate for use in examining the role of PI 3-kinase in co- 
stimulation. 
Discussion 
By binding to PI 3-kinase, GRB-2/SOS, and ITK, CD28 
has the potential to engage multiple signaling pathways 
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Figure 7. Wortmannin Induces Apoptosis in the DC27 Cells 
Wild-type human CD28 transfectant was incubated with or without 
wortmannin at different concentrations. 
(A) Cell proliferation (13H]-Tdr incorporation) and viability (trypan blue 
exclusion) were monitored after 24 hr culture of cells in the presence 
of various concentrations of wortmannin. 
(6) Inhibition of lipid kinase activity. After 2 hr of exposure to wortman- 
nin, DC27 cells transfected with hCD28 were subjected to immunopre- 
cipitation with either anti-CD28 (top) or anti-p85 (bottom), labeled in 
a lipid kinase assay. The intensity of each PI-P spot was also measured 
and expressed as a percentage of that in the absence of wortman- 
nin (A). 
(C) DNA fragmentation was measured after 4 hr of cell culture in the 
absence or presence of different concentrations of wortmannin (O- 
600 nM). Cells were solubilized and subjected to phenol/chloroform 
extraction and RNAse treatment. Digested DNA was then separated 
on agarose gel and visualized with ethidium bromide staining. During 
these experiments, a DMSO concentration equivalent to that con- 
tained in the highest concentration of wortmannin was used as a 
control. 
in T cells. In turn, different signals may be linked to CD28- 
regulated events, such as increased lymphokine produc- 
tion and the expression of CTLA4 and the CD40 ligand. 
Mutation of residue Y-191 has been reported to prevent 
anti-CD28-induced IL-2 in a T cell hybridoma (Pages et 
al., 1994). However, this study did not distinguish between 
the relative roles of PI 3-kinase, GRB9/SOS, and ITK bind- 
ing in TCRICD3-CD28 coregulation of IL-2 production. 
Both PI 3-kinase and GRB-2 bind to CD28 pYMNM motif 
(Prasad et al., 1994; Truitt et al., 1994; Schneider et al., 
1995a). Here, we have demonstrated that a mutation 
(M-l 94C) that selectively disrupts PI 3-kinase binding with- 
out altering GRB-2 or ITK binding markedly reduces IL-2 
production. In this system, lymphokine production depended 
on signals from TCRI;ICD3 and CD28 using concentra- 
tions of MAb that approximate physiological ligand. Muta- 
tions at Y-191 and M-194 markedly reduced (by at least 
90%) the ability of anti-CD3 plus CD86 to induce IL-2 se- 
cretion and, concordantly, to recruit the kinase (Figures 
3-5). A small but reproducible induction of IL-2 was ob- 
served in the absence of PI 3-kinase binding. In both Tcells 
and insect cells, the mutation of M-194 in CD28 resulted in 
a marked decrease in binding (Figures 5 and 6). Signifi- 
cantly, while the M194CD28C mutant failed to bind to PI 
3-kinase, it retained an ability to bind to GRB-2 and ITK 
(Figure 6). CD26 recruitment of PI 3-kinase therefore pro- 
vides a cosignal in the signaling cascade linked to IL-2 
production. A less likely possibility is that another unidenti- 
fied SH2 domain carrying protein with the same binding 
requirements as PI 3-kinase exists in T cells. 
Previous studies using the inhibitor of PI 3-kinase, wort- 
mannin, have yielded conflicting results (Ward et al., 1995; 
Lu et al., 1995). This discrepancy underlines the impor- 
tance of our mutational analysis. While the basis of this 
discrepancy is unclear, inhibition was observed in cultures 
stimulated by the combination of anti-CD3 plus CD80, but 
not with combinations of CD28 plus phorbol ester (Ward 
et al.,1995). This is consistent with our results showing a 
dependency of anti-CD3 plus CHO-CD86 cosignaling on 
associated PI 3-kinase. The insensitivity to combinations 
of anti-CD28 plus phorbol ester to the inhibitor may be 
related to pleiotropic effects of phorbol ester on additional 
signaling pathways. Under the circumstances in which 
wortmannin inhibited costimulation, it was unclear whether 
TCRgCD3 or CD28 signaling was the target of inhibition. 
In our study, the lossof IL-2 production with the MlwCD28C 
mutant occurred without any disruption of the TCRrJCD3 
pathway, thereby directly implicating PI 3-kinase in the 
CD28 signaling arm of CD28-TCR stimulation. In our sys- 
tem, concentrations of wortmannin from 20-200 nM inhib- 
ited CD28-associated PI 3-kinase as well as free PI 3-ki- 
nase from cells treated with the reagent (Figure 78). The 
lack of complete inhibition may be due to incomplete up- 
take or sequestration of the kinase in intracellular vesicles, 
since the same concentrations of reagent completely in- 
hibited lipid kinase activity when added to in vitro precipi- 
tates (data not shown). Significantly, concentrations as 
low as 20 nM induced apoptosis as detected by extensive 
DNA fragmentation (Figure 7C). Wortmannin was there- 
fore not suitable for a study of the role of PI 3-kinase in 
CDP&induced IL-2 production in our costimulation 
assays. Wortmannin has also been reported to induce 
apoptosis in PC1 2 cells (Yao and Cooper, 1995). 
By what intracellular mechanism might PI 3-kinase regu- 
late IL-2 production? PI 3-kinase has been reported to bind 
and activate ~21’~~ (Sjolander et al., 1991; Rodriguez- 
Viciana et al., 1994; Hu et al., 1995). This could connect 
PI 3-kinase to a signaling pathway mediated by p21rBs and 
its regulation of MAPK and JNK. p21’@, MAPK, and JNK 
are activated by CD28 ligation (August and DuPont, 1994; 
Nunes et al., 1994; Su et al., 1994). JNK phosphorylates 
cJun, thereby increasing AP-1 transcriptional activity 
within the IL-2 promoter (Derijard et al., 1994). In agree- 
ment, oncogenic Ras induces IL-2 production (Rayter et 
al., 1992; Baldari et al., 1993). Further, AP-1 transcrip- 
tional activity in transgenic mice carrying a reporter gene 
requires CD28-mediated signals (Rincon and Flavell, 
1994). In this context, it is intriguing that GRB-2/SOS, an- 
other regulator of Ras, also binds to CD28 (Schneider et 
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al.,1 995a). CD28 therefore engages two intracellular pro- 
teins with the potential to activate the ~21’~) pathway. 
GRB-2 binding does not prevent PI 3-kinase binding, and 
vice versa (Schneider et al. 1995a). A role for PI 3-kinase 
in IL-2 induction does not exclude a role for GRB-21SOS. 
PI 3-kinase and GRB-2/SOS may function cooperatively, 
or they may depend on each other. Alternatively, GRB-PI 
SOS may be involved in other functions attributed to CO28. 
We are presently examining whether mutations that inter- 
fere with GRB-2 binding also block IL-2 production. 
In an alternate pathway, PI 3-kinase may produce D-3 
phospholipids PI 3,4-P2 and PI 3,4,5-P3 and regulate pro- 
tein kinase C c (PKCQ (Nakanishi et al., 1993). PI 3-kinase 
binding to the PDGF-R is also required for the activation 
of p70SBK (Chung et al., 1994). We and others previously 
showed that the p59vn and p56rck SH3 domains bind to PI 
3-kinase, and may recruit the enzyme to the TCRLJCD3 
and CD4 receptors (Prasad et al., 1993a, 1993b; Vogel and 
Fujita, 1993). PI 3-kinase also becomes activated upon 
binding to the SH3 domain (Pleiman et al., 1994). Further, 
both TCR and CD28 ligation independently generate D-3 
phosphoinositides (Ward et al., 1995). p59m and ~56”~ 
and CD28 binding differs quantitatively, where the CD28 
binds several-fold more enzyme than the CD4-lck and 
TCR/CD3-p59vn complexes. In this sense, CD28 may ad- 
just the threshold of signaling by supplementing subopti- 
mal signals generated by the TCRgCD3-CD4 complex 
(Rudd et al., 1994; Schneider et al., 1995c). At low antigen 
concentrations, this additive signal might provide suffi- 
cient additional signal to surpass a threshold requirement 
that distinquishes between responsiveness from nonre- 
sponsiveness. 
In addition to PI 3-kinase and GRB-2, ITK has been re- 
ported to bind CD28 (August et al., 1994). The molecular 
basis of this interaction is unclear. Although we have had 
difficulty observing ITK binding to CD28 in T cells (data 
not shown), we could demonstrate binding in insect cells. 
In this system, p561Ck and p59b” can regulate the binding 
of ITK, placing ITK downstream of the src kinases in a 
signaling cascade (Raab et al., 1995). Unlike PI 3-kinase 
and GRB-2, we found that the disruption of the pYMNM 
motif still allowed for the binding of ITK to CD28 (Figure 
6) possibly implicating other phosphotyrosine sites such 
as Y-206, Y-209, or Y218. It remains to be determined 
whether other CD28-mediated functions such as the in- 
duction of CTLA4 and CD40L expression are linked to 
ITK, to PI 3-kinase and GRB-2-mediated signal transduc- 
tion, or both. 
CTLA4 has been found to bind to PI 3-kinase by means 
of a pYVKM motif (Schneider et al., 1995b). While CTLA4 
has the capacity to generate negative signals (Bluestone 
et al., 1994) under other circumstances, CTLA4 may co- 
operate with CD28 in the production of IL-2 (Linsley et al., 
1992b). The finding that PI 3-kinase is a component in the 
regulation of IL-2 supports that notion that CTLA-4 may in 
certain situations also play a positive role in T cell growth. 
Experimental Procedures 
Cells, Reagents, and Antibodies 
The murine T cell hybridoma, DC27 (gift of Dr. Ft. Zamoyska, Medical 
Research Council, London) was cultured in RPM1 1640 medium sup- 
plemented with 5% (v/v) fetal bovine serum (FES, Intergen, New York) 
and 50 uM 2-mercaptoethanol. CHO and CHO-CD86, which express 
high levels of transfected murine CD86 (Chen et al., 1994a), were 
grown in DMEM medium with 5% FBS. Anti-murine CD3 (2Cil) was 
from American Type Culture Collection; anti-murine CD28 (37.51) was 
provided by Dr. J. Allison (University of California, Berkeley) (Harding 
et al., 1992); anti-murine CD66 (87-2) (2DiO) is as described (Chen 
et al., 1994b); anti-CD28 (L293) was from Becton Dickinson (San Jose, 
California); anti-HA (12CA5) was from the Harvard Cell Culture Facility 
(Boston); and anti-GRBP was from Transduction Laboratories. Wort- 
mannin was purchased from Sigma. Other reagents and their sources 
are as described (Prasad et al., 1994). 
Transfections of Human CD28 
The plasmids of human CD28 wild-type and Yigl and M184 mutants 
have been described before (Prasad et al., 1994). The inserts were 
resubcloned into the SRa expression vector (Takebe et al., 1988). 
Human CD28 plasmids were cotransfected by electroporation at 260 
V and 1600 uF with pSVneo, which contains a neomycin resistance 
gene. Cells were selected with 1.5 mglml of G418 for 2 weeks, and 
cells from different populations were assayed for human CD28 expres- 
sion by FACS. 
Cell Flow Cytometry Analysis 
Cytometric analysis was carried out as described (Prasad et al., 1994). 
In brief, cells (5 x 105) were stained with antibodies for 1 hr on ice, 
washed twice, and were then incubated with secondary fluorescein 
isothiocyanate (FITC)-labeled antibodies under the same conditions. 
Cytometric analysis was conducted using an EPICS cell sorter (Coulter 
Corporation). 
Biotinylation and lmmunopreclpitation Analysis of Cell 
Surface Proteins 
Cells were washed with Biwa’s buffer (1 mM MgCk and 0.1 mM CaCk 
in phosphate-buffered saline [pH 7.21). Cells were then incubated at 
room temperature with 150 mM NaCI, 10 mM sodium borate, and 66 
Kg/ml Sulfo-NHS-biotine (pH 8.8) (Pierce) for 20 min, followed by 
washing with 25 mM L-lysine in Biwa’s buffer. Cells were lysed in 1% 
NP40 (VN) lysis buffer with 1 mM PMSF and subjected to immunopre- 
cipitation (Prasad et al., 1994). Biotinylated CD28 were detected with 
streptavidin coupled with horseradish peroxidase and chemilumines- 
cence. 
CD28 Cross-Linking and lmmunopreclpitation 
CHO and CHO-CD86 cells were grown on 150 mm plates to conflu- 
ence, washed once, and 150 x 1 d of DC27 transfectants were layered 
on top of these cells in 5 ml media. These plates were then incubated 
at 37OC for the indicated time before harvesting. Cells were washed 
oncewith cold phosphate-buffered saline, followed by lysis in 1% NP40 
plus vanadate and PMSF. Cell lysates were precleared by incubation 
with pansorbin cells (Calbiochem) on ice for 30 min, followed by immu- 
noprecipitation with pre-bound antibody-protein G/A sepharose beads 
for 2 hr. The beads were washed with lysis buffer three times before 
lipid kinase assay or electrophoresis was conducted. 
Lipid Klnase Assay and Western Blot Analysis 
For lipid kinase assay, immunoprecipitates were further washed with 
LICI and TNE (10 mM Tris [pH 7.51, 150 mM NaCI, 1 mM EGTA), 
followed by lipid kinase reaction and separation on TLC plates as 
described (Prasad et al.. 1994). For Western blot, immunoprecipitates 
were boiled in loading buffer, and proteins were separated on SDS- 
PAGE and transfered onto nitrocellulose membrane. Following blot- 
ting with the first antibody, reactivities were detected with horseradish 
peroxidase-conjugated antibodies and chemiluminescence as de- 
scribed (Amersham). The relative intensity of each band on films was 
determined by LKB UltroScan. 
Expresslon and lmmunoprecipltation of Human CD28 in 
Sf21 Calls 
Expression in Sf21 cells by baculovirus system was performed as 
described (Raab et al., 1994). In brief, human CD28 (gifl of Dr. B. 
Seed, Massachusetts General Hospital, Boston), Lck, GRBP, and 
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hemaglutinin-tagged ITK (HA-tagged ITK) (gift of Dr. L. Berg, Harvard 
University) constructs were subcloned into the pV11393 vector, and 
recombinant viruses were obtained from the S. frugiperda cell line by 
cotransfection with wild-type baculoviral DNA. Following infection of 
Sf21 cells with different combinations of recombinant viruses, human 
CD28 were immunoprecipitated from cell lysates with L293, and CD28- 
associated proteins were analyzed by Western blot hybridization. 
Costimulation of T Cell Transfectants 
CHO or CHO-CD86 cells were plated at 5 x lo3 /well in 96-well plates 
and cultured overnight. Cells were washed twice and incubated with 
DC27 transfectants at 1 x 105/well plus 2Cll at indicated concentra- 
tions. The final volume was 200 ul/well. Each condition was assayed 
as a triplicate. Cells were then cultured for 24 hr before the superna- 
tants were removed for the measurement of IL-2. Cell growth at this 
point was assayed by 1 hr pulse with 1 pCi of PHjthymidine, followed 
by harvesting and counting in scintillation fluid. 
IL-2 Assay 
The supernatants derived from cell cultures were stored at -70°C and 
thawed before IL-2 assay. CTLL-2 cells were grown in the presence 
of recombinant human 11-2. They were washed three times and plated 
at 2500 cells/well in a 96well plate. A series of P-fold diluted superna- 
tants were added to CTLL-2 cells. Cells were cultured for 24 hr followed 
by an 18 hr pulsing with 1 t&i of PH)thymidine before harvesting and 
counting. The amount of IL-2 in these supernatants was determined 
by comparing with the standard curve established with recombinant 
IL-2. The half-maximum of stimulation is defined as 100 U/ml as de- 
scribed (Gillis et al., 1978). 
Trypan Blue Staining and DNA Fragmentation 
Cell viability was determined with 0.04% trypan blue staining and 
counting of triplicates under microscopy. For DNA fragmentation, cells 
were incubated with 1% NP40 plus PMSF lysis buffer for 30 min. 
Soluble materials were collected after 10 min centrifugation and sub- 
jected to phenol and chloroform extraction, followed by ethanol precipi- 
tation. The resulting DNA solutions were incubated with RNAse at 
37°C for 30 min to remove RNA, and DNA was then resolved on 1.2% 
agarose gel. The gel was stained with ethidium bromide (Sigma) and 
photographed. 
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